Mostrar el registro sencillo del ítem

Farmacoterapéutica de la anticoagulación. Revisión de la literatura

Farmacoterapéutica de la anticoagulación. Revisión de la literatura

dc.creatorPosada-López, Andrés Felipe
dc.creatorGarcía C.,, Julio César
dc.creatorPacheco P., Tatiana
dc.creatorArias V., Sara
dc.date2017-04-25
dc.date.accessioned2020-08-21T20:23:26Z
dc.date.available2020-08-21T20:23:26Z
dc.identifierhttps://revistacolombianadeenfermeria.unbosque.edu.co/article/view/2029
dc.identifier10.18270/rce.v14i12.2029
dc.identifier.urihttp://test.repositoriodigital.com:8080/handle/123456789/10626
dc.descriptionLa terapia anticoagulante tiene múltiples indicaciones en diversos contextos; va más allá de la prevención de la formación de trombos o su propagación y tiene como objetivo final mejorar la calidad de vida de los pacientes. En efecto, la anticoagulación se hace relevante en diversas situaciones clínicas que abarcan desde enfermedades crónicas hasta patologías quirúrgicas y situaciones especiales (obesidad, enfermedad renal crónica, trauma, cáncer) para evitar desenlaces adversos, tales como el tromboembolismo venoso, los estados hipercoagulables, el síndrome coronario agudo, la fibrilación y el aleteo (flutter) auricular, entre otros. En este sentido, la comprensión adecuada y la formulación de dosis óptimas de anticoagulantes recobran especial importancia. El objetivo de este trabajo fue revisar la evidencia proveniente de estudios clínicos sobre el papel de los principales anticoagulantes orales y parenterales en el contexto de los pacientes con indicación de anticoagulación por antecedentes patológicos, quirúrgicos y en situaciones especiales como las mencionadas. Existen diversos conceptos y recomendaciones sobre la profilaxis y el tratamiento anticoagulante en indicaciones habituales; sin embargo, se debe establecer un consenso de anticoagulación en situaciones especiales que se presentan en la práctica clínica diaria.  es-AR
dc.descriptionLa terapia anticoagulante tiene múltiples indicaciones en diversos contextos; va más allá de la prevención de la formación de trombos o su propagación y tiene como objetivo final mejorar la calidad de vida de los pacientes. En efecto, la anticoagulación se hace relevante en diversas situaciones clínicas que abarcan desde enfermedades crónicas hasta patologías quirúrgicas y situaciones especiales (obesidad, enfermedad renal crónica, trauma, cáncer) para evitar desenlaces adversos, tales como el tromboembolismo venoso, los estados hipercoagulables, el síndrome coronario agudo, la fibrilación y el aleteo (flutter) auricular, entre otros. En este sentido, la comprensión adecuada y la formulación de dosis óptimas de anticoagulantes recobran especial importancia. El objetivo de este trabajo fue revisar la evidencia proveniente de estudios clínicos sobre el papel de los principales anticoagulantes orales y parenterales en el contexto de los pacientes con indicación de anticoagulación por antecedentes patológicos, quirúrgicos y en situaciones especiales como las mencionadas. Existen diversos conceptos y recomendaciones sobre la profilaxis y el tratamiento anticoagulante en indicaciones habituales; sin embargo, se debe establecer un consenso de anticoagulación en situaciones especiales que se presentan en la práctica clínica diaria.  es-ES
dc.formatapplication/pdf
dc.languagespa
dc.publisherUniversidad El Bosquees-ES
dc.relationhttps://revistacolombianadeenfermeria.unbosque.edu.co/article/view/2029/1563
dc.relation/*ref*/Kahn SR, Morrison DR, Cohen JM, Emed J, Tagalakis V, Roussin A, et ál. Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism. Cochrane Database Syst Rev. 2013 jul.;7: 1-178.
dc.relation/*ref*/Dennis RJ, Roa JH, Villadiego J, Méndez F, Vieda E, Restrepo H. Venous thromboembolism prophylaxis in Colombian surgical and medical patients: results for Colombia of the Endorse study. Biomédica. 2011 jun.;31(2):200-8.
dc.relation/*ref*/Vardi M, Haran M. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score: a rebuttal. J Thromb Haemost. 2011 jul.;9(7):1437-8.
dc.relation/*ref*/Evidence-Based Medicine Working Group. Evidencebased medicine. A new approach to teaching the practice of medicine. JAMA. 1992;268:2420-5.
dc.relation/*ref*/Barbar S, Noventa F, Rosseto V, Ferrari A, Brandolin B, Pertali M et ál. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8: 2450-7.
dc.relation/*ref*/Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg. 2010 febr.;251(2):344-50.
dc.relation/*ref*/Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol. 2001;38:12-9.
dc.relation/*ref*/Green-top guideline n.o 37: reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Londres: RCOG; 2009.
dc.relation/*ref*/Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium – a register-based case-control study. American Journal of Obstetrics and Gynecology. 2008;198:233e1-7e.
dc.relation/*ref*/Blondon M. Thromboprophylaxis after cesarean section: decision analysis. Thrombosis Research. 2011;127(Supl. 3):S9-12.
dc.relation/*ref*/Kearon C, Aki E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H et ál. Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report. CHEST. 2016;149(2):315-52.
dc.relation/*ref*/Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP et ál. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2189-204.
dc.relation/*ref*/Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015 en. 2; 33: 654-656.
dc.relation/*ref*/Zachary Y, Roberts C. Thromboprophylaxis after multiple trauma: What treatment and for how long? International Journal of the Care of the Injured. 2009. 40S3: S90-S94.
dc.relation/*ref*/Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AJ et ál. Factors at admission associated with bleeding risk in medical patients: findings from the improve investigators. Chest. 2011 en.;139(1):69-79.
dc.relation/*ref*/Spyropoulos AC, Anderson FA Jr, Fitzgerald G, Decousus H, Pini M, Chong BH et ál. Predictive and associative models to identify hospitalized medical patients at risk for venous thromboembolism. Chest. 2011; 140: 706-714.
dc.relation/*ref*/January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr et ál. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 dic. 2;130(23):2071-104.
dc.relation/*ref*/Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest. 2010 febr.;137(2):263-72.
dc.relation/*ref*/Sun JC, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet. 2009 ag.15;374(9689):565-76.
dc.relation/*ref*/Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Haemost. 2007;98:790-7.
dc.relation/*ref*/You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC et ál. Evidence-based clinical practice guidelines ed: American College of Chest Physicians Therapy and Prevention of Thrombosis, 9th Oral Anticoagulant Therapy: Antithrombotic. Chest. 2012;141:e44S-e88S.
dc.relation/*ref*/Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002-12.
dc.relation/*ref*/Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl CM, Brubacher JR et ál. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ. 2008;178(12):1563-9.
dc.relation/*ref*/Hill CE, Duncan A. Overview of pharmacogenetics in anticoagulation therapy. Clin Lab Med. 2008;28:513-24.
dc.relation/*ref*/Butchart EG. Antithrombotic management in patients with prosthetic valves: a comparison of American and European guidelines. Heart. 2009;95:430-6.
dc.relation/*ref*/Rogers FB, Cipolle MD, Velmahos G, Rozycki G, Luchette FA. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: EAST practice management guidelines work group. J Trauma. 2002 jul.;53(1):142-64.
dc.relation/*ref*/Latronico N, Berardino M. Thromboembolic prophylaxis in head trauma and multiple-trauma patients. Minerva Anestesiol. 2008 oct.;74(10):543-8.
dc.relation/*ref*/Douketis JD. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians. Thrombosis Research. 2002;108(1):3-13.
dc.relation/*ref*/Holbrook A, Schulman S, Witt DM, Vandvik PO, Lane DA, Eckman MH et ál. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141 Issue 2, Supplement: e152Se184S.
dc.relation/*ref*/García JC. Sobreanticoagulación. Medicina interna en urgencias. 2.a ed. Bogotá: Celsus; 2013.
dc.relation/*ref*/Riess H, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Haemost. 2007;98:790-7.
dc.relation/*ref*/Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors development. Clin Pharmacokinet. 2009;48:1-22.
dc.relation/*ref*/Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg M. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. The American Journal of Cardiology. 2012;110(3), 453-60.
dc.relation/*ref*/Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S et ál. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 dic.;45(12):3754-832.
dc.relation/*ref*/Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007 febr.;38(2):423-30.
dc.relation/*ref*/Kashuk JL, Moore EE, Johnson JL, Biffl WL, Burlew CC, Barnett C et ál. Progressive postinjury thrombocytosis is associated with thromboembolic complications. Surgery. 2010 oct.;148(4):667-74.
dc.relation/*ref*/Wang AY, Ivany JN, Perkovic V, Gallagher MP, Jardine MJ. Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials. Nephol Dial Transplant. 2013;28:2875-88.
dc.relation/*ref*/Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br J Haematol. 2011 oct.;155(2):137-49.
dc.relation/*ref*/Kornblith LZ, Howard B, Kunitake R, Redick B, Nelson M, Cohen MJ, Callcut R. Obesity and clotting: body mass index independently contributes to hypercoagulability after injury. J Trauma Acute Care Surg. 2015 en.;78(1):30-8.
dc.relation/*ref*/Mueller JA, Patel T, Halawa A, Dumitrascu A, Dawson NL. Warfarin dosing and body mass index. Ann Pharmacother. 2014 my.;48(5):584-8.
dc.relation/*ref*/Wallace JL, Reaves AB, Tolley EA, Oliphant CS, Hutchison L, Alabdan NA et ál. Comparison of initial warfarin response in obese patients versus non-obese patients. J Thromb Thrombolysis. 2013 jul.;36(1):96-101.
dc.relation/*ref*/Hoffmann P, Keller F. Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis. Eur J Clin Pharmacol. 2012;68: 757-65.
dc.relation/*ref*/Wang TF, Milligan PE, Wong CA, Deal EN, Thoelke MS, Gage BF. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost. 2014 en.;111(1):88-93.
dc.relation/*ref*/Willett KC, Alsharhan M, Durand C, Cooper MR. Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients. Ann Pharmacother. 2013dic.;47(12):1717-20.
dc.relation/*ref*/Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Lowmolecular- weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009jun.;43(6):1064-83.
dc.relation/*ref*/Pon TK, Dager WE, Roberts AJ, White RH. Subcutaneous enoxaparin for therapeutic anticoagulation in hemodialysis patients. Thrombosis Research. 2014;133:1023-8.
dc.relation/*ref*/Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol. 2004;15:3192-206.
dc.relation/*ref*/Schmid P, Brodmann D, Odermatt Y, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. J Thromb Haemost. 2009;7(10):1629.
dc.relation/*ref*/Samama MM. Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment. Drugs Aging. 2011 mzo. 1;28(3):177-93.
dc.relation/*ref*/Schmid P, Fischer AG, Wuillemin WA. Low molecular weight heparin in patients with renal insufficiency. Swiss Med Wkly. 2009;139:438-52.
dc.relation/*ref*/Bauersachs RM. Use of anticoagulants in elderly patients. Thromb Res. 2012febr.;129(2):107-15.
dc.relation/*ref*/Robert-Ebadi H, Le Gal G, Righini M. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging. 2009;4:165-77.
dc.relation/*ref*/Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014my.;62(5):857-64.
dc.relation/*ref*/Hill J, Treasure T. Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance. British Medical Journal. 2010; 340:c95.
dc.relation/*ref*/Siguret V, Gouin-Thibault I, Gaussem P, Pautas E. Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly. Drugs Aging. 2013sept.;30(9):687-99.
dc.relation/*ref*/Knight M; UKOSS. Antenatal pulmonary embolism: risk factors, management and outcomes. BJOG. 2008 mzo.;115(4):453-61.
dc.relation/*ref*/Dargaud Y, Rugeri L, Vergnes MC, Arnuti B, Miranda P, Negrier C et ál. A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study. British Journal of Haematology. 2009;145:825-35.
dc.relation/*ref*/Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V et ál. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170(19):1710-6.
dc.relation/*ref*/Bendinelli C, Balogh Z. Postinjury thromboprophylaxis. Curr Opin Crit Care. 2008dic.;14(6):673-8.
dc.relation/*ref*/Lu JP, Knudson MM, Bir N, Kallet R, Atkinson K. Bivalirudina for prevention of venous thromboembolism in high risk trauma patients: a pilot study. J Am Coll Surg. 2009 nov.;209(5):589-94.
dc.relation/*ref*/Arnold JD, Dart BW, Barker DE, Maxwell RA, Burkholder HC, Mejia VA. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients. Am Surg. 2010 jun.;76(6):563-70.
dc.relation/*ref*/Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 my. 15;111(10):4902-7.
dc.relation/*ref*/Petralia GA, Kakkar AK. Treatment of venous thromboembolism in cancer patients. Semin Thromb Hemost. 2007 oct.;33(7):707-11.
dc.relation/*ref*/Queensland Health. Guideline for anticoagulation and prophylaxis using low molecular weight heparin. State of Queensland. 2014. Document Number # QH-GDL-95.
dc.relation/*ref*/Trujillo-Santos J, Nieto JA, Ruiz-Gamietea A, López- Jiménez L, García-Bragado F, Quintavalla R et ál. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res. 2010 abr.;125 Supl. 2:S58-61.
dc.sourceRevista Colombiana de Enfermería; Vol 14 (2017): Revista Colombiana de Enfermería; 65-81en-US
dc.sourceRevista Colombiana de Enfermería; ##issue.vol## 14 (2017): Vol. 14, Año 12 (2017); 65-81es-AR
dc.sourceRevista Colombiana de Enfermería; Vol. 14 (2017): Revista Colombiana de Enfermería; 65-81es-ES
dc.sourceRevista Colombiana de Enfermería; v. 14 (2017): Revista Colombiana de Enfermería; 65-81pt-BR
dc.source2346-2000
dc.source1909-1621
dc.source10.18270/rce.v14i0
dc.subjectCoagulaciones-ES
dc.subjectAnticoagulanteses-ES
dc.subjectAgregación plaquetariaes-ES
dc.subjectWarfarinaes-ES
dc.subjectHeparinaes-ES
dc.subjectHeparina de bajo peso musculares-ES
dc.subjectterapeuticaes-ES
dc.titleFarmacoterapéutica de la anticoagulación. Revisión de la literaturaes-AR
dc.titleFarmacoterapéutica de la anticoagulación. Revisión de la literaturaes-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem